A PHASE I TRIAL OF TARGETED IMMUNOTHERAPY WITH DARATUMUMAB FOLLOWING MYELOABLATIVE TOTAL BODY IRRADIATION (TBI)-BASED CONDITIONING AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATON IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH HIGH-RISK T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOMA (T- ALL/T-LLy) (ALLO-T-DART) (IND 159396): A PTCTC FACILITATED STUDY. (October 2022) - Quigg, T.; Flower, A.; Teachey, D.; Lim, M.; Chu, Y.; Harrison, L.; Morris, E.; Gardenswartz, A.; Hochberg, J.; Ozkaynak, M.; Rosenblum, J.; Milner, J.; et al.